Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Head & Neck 1Gastrointestinal 1

Conditions

Lung Neoplasms 2Small Cell Lung Carcinoma 1Liver Neoplasms 1Hypoxia 1Head and Neck Neoplasms 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × fluoromisonidazole × Thoracic × Clear all
NCT00544674 2012-12-10

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

Proacta, Incorporated

Phase 2 Terminated
5 enrolled 7 charts
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT01213030 2012-09-25

Clinical Evaluation of the New Hypoxia Imaging Agent HX4

Siemens Molecular Imaging

Phase 1/2 Completed
12 enrolled
GastrointestinalHead & NeckThoracic

Hypoxia, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡